Use of NONRATT021972 small interfering RNA in preparation of drug for treating diabetes mellitus with cardiac autonomic nervous system diseases

Abstract

The invention discloses a use of a long non-coding ribonucleic acid NONRATT021972 small interfering RNA in preparation of a drug for treating diabetes mellitus with cardiac autonomic nervous system diseases. An experiment observation result shows that the long non-coding ribonucleic acid NONRATT021972 small interfering RNA can improve diabetic model rat cardiac function anomalous change, reduce risen blood sugar, a serum inflammatory factor level and an oxidative stress level, and improve antioxidation substance activity. Through long non-coding ribonucleic acid NONRATT021972 small interfering RNA-based treatment, up-regulated expression of diabetic model rat superior cervical ganglia gap junction hemichannel protein 1 (Pannexin-1) is substantially inhibited, insulin receptor substrate-1 (IRS-1) abnormal serine 302 phosphorylation is inhibited and down-regulated IRS-1 expression is improved. The NONRATT021972 small interfering RNA can be used in Pannexin-1 and IRS-1 dysfunction mediated disease treatment drugs. The long non-coding ribonucleic acid NONRATT021972 small interfering RNA in forms of an oral medicine, an injection, a lozenge or other local or whole body agents can prevent and treat the above diseases.

Description

technical field [0001] The invention relates to the invention field of the application of drugs for diabetes complicated with cardiac autonomic neuropathy. Background technique [0002] Diabetes Mellitus (DM) is a group of metabolic clinical syndromes. With the development of society and the improvement of people's living standards, the prevalence of diabetes increases year by year. In developed countries, the prevalence of diabetes has reached 3%-7%. It has become the fourth priority disease after cancer, AIDS, and cardiovascular and cerebrovascular diseases, and has become the fifth leading cause of death in the world. Diabetes is divided into type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes. It is estimated that one in six people worldwide is at risk of complications from diabetes. Type 2 diabetes accounts for more than 90% of the diabetic population in my country, which seriously affects people's health and social development. Diabetic autonomic ...

AI Technical Summary

Problems solved by technology

Phosphorylation of IRS is very important for the transduction of insulin signaling pathway. Phosphorylation of its tyrosine site can make the signal conduct normally, but the phosphorylation of abnormal serine of IRS often leads to the degradation of IRS and interferes with the transduction of insulin signal, which may is an important molecular mechanism that causes insulin resistance

Images